


PRODUCT INFORMATION



Cevimeline (hydrochloride)

Item No. 17802

CAS Registry No.: 107220-28-0
Formal Name: (2'R,3R)-rel-2'-methyl-spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], monohydrochloride
Synonyms: AF 102B, SNI 2011, SNK 508
MF: C₁₀H₁₇NOS • HCl
FW: 235.8
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cevimeline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the cevimeline (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Cevimeline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of cevimeline (hydrochloride) in ethanol and DMSO is approximately 5 mg/ml and approximately 3 mg/ml in DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of cevimeline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of cevimeline (hydrochloride) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Cevimeline is a muscarinic receptor agonist (EC₅₀s = 23, 48, and 63 nM for M₁, M₃, and M₅, respectively, and >1 μM for M₂ and M₄).¹ It stimulates secretion by salivary glands and is useful in ameliorating xerostomia (dry mouth).^{2,3}

References

1. Heinrich, J.N., Butera, J.A., Carrick, T., *et al.* Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists. *Eur. J. Pharmacol.* **605(1-3)**, 53-56 (2009).
2. Kahn, S.T. and Johnstone, P.A. Management of xerostomia related to radiotherapy for head and neck cancer. *Oncology (Williston Park)* **19(14)**, 1827-1832 (2005).
3. Ramos-Casals, M., Tzioufas, A.G., Stone, J.H., *et al.* Treatment of primary Sjögren syndrome: A systematic review. *JAMA* **304(4)**, 452-460 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM